MedTrace Logo

Treatment Resistant Bipolar Depression

NCT00272025 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2015-12-16

No results posted yet for this study

Summary

To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.

Conditions

Interventions

DRUG

Escitalopram

10mg to 20mg tablet daily for 6 weeks

DRUG

placebo

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • Roumen V. Milev, MD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272025 on ClinicalTrials.gov